# Giuseppe LImongelli

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 281 papers | 9,919 citations | 47 h-index | 92 g-index |
| 320 ext. papers | 12,694 ext. citations | 4 avg, IF | 5.6 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 281 | Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes.. *Journal of Clinical Medicine*, **2022**, 11, | 5.1 | 3 |
| 280 | The Risk of Sudden Unexpected Cardiac Death in Children: Epidemiology, Clinical Causes, and Prevention. *Heart Failure Clinics*, **2022**, 18, 115-123 | 3.3 | 4 |
| 279 | The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2022**, 18, 1-8 | 3.3 | 0 |
| 278 | The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis. *Heart Failure Clinics* , **2022**, 18, 61-72 | 3.3 | 1 |
| 277 | Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. *Heart Failure Clinics*, **2022**, 18, 31-37 | 3.3 | 4 |
| 276 | Cardiovascular Involvement in mtDNA Disease: Diagnosis, Management, and Therapeutic Options. *Heart Failure Clinics*, **2022**, 18, 51-60 | 3.3 | 3 |
| 275 | Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. *Heart Failure Clinics*, **2022**, 18, 39-49 | 3.3 | 4 |
| 274 | Clinical Manifestations of 22q11.2 Deletion Syndrome. *Heart Failure Clinics*, **2022**, 18, 155-164 | 3.3 | 4 |
| 273 | Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. *Heart Failure Clinics*, **2022**, 18, 73-87 | 3.3 | 3 |
| 272 | Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management. *Heart Failure Clinics*, **2022**, 18, 19-29 | 3.3 | 2 |
| 271 | The Heart Muscle and Valve Involvement in Marfan Syndrome, Loeys-Dietz Syndromes, and Collagenopathies. *Heart Failure Clinics*, **2022**, 18, 165-175 | 3.3 | 1 |
| 270 | Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. *Neurology International*, **2022**, 12, 102-108 | 0 | |
| 269 | Clinical and Molecular Characteristics of Patients with PLN R14del Cardiomyopathy: State-of-the-Art Review. *Neurology International*, **2022**, 12, 112-121 | 0 | |
| 268 | Pancarditis as the Clinical Presentation of Eosinophilic Granulomatosis with Polyangiitis: A Multimodality Approach to Diagnosis. *Neurology International*, **2022**, 12, 133-141 | 0 | 0 |
| 267 | Modified Body Mass Index as a Novel Nutritional and Prognostic Marker in Patients with Cardiac Amyloidosis. *Neurology International*, **2022**, 12, 185-197 | 0 | 0 |
| 266 | Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry.. *Internal and Emergency Medicine*, **2022**, 1 | 3.7 | 0 |
| 265 | Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010075 | 6.4 | 0 |

| | | | |
|---|---|---|---|
| 264 | Clinical application of CMR in cardiomyopathies: evolving concepts and techniques : A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology.. *Heart Failure Reviews*, **2022**, 1 | 5 | 1 |
| 263 | Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic´Cardiomyopathy.. *Journal of the American College of Cardiology*, **2022**, 79, 1986-1997 | 15.1 | 1 |
| 262 | 22q11.2 Deletion Syndrome: Impact of Genetics in the Treatment of Conotruncal Heart Defects. *Children*, **2022**, 9, 772 | 2.8 | 0 |
| 261 | Thoracic Aortic Dilation: Implications for Physical Activity and Sport Participation. *Diagnostics*, **2022**, 12, 1392 | 3.8 | 1 |
| 260 | Impact of hard lockdown on interventional cardiology procedures in congenital heart disease: a survey on behalf of the Italian Society of Congenital Heart Disease. *Journal of Cardiovascular Medicine*, **2021**, 22, 701-705 | 1.9 | 0 |
| 259 | Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. *Journal of Cardiovascular Echography*, **2021**, 31, 157-164 | 0.6 | 1 |
| 258 | The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. *Orphanet Journal of Rare Diseases*, **2021**, 16, 374 | 4.2 | |
| 257 | The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy. *Orphanet Journal of Rare Diseases*, **2021**, 16, 374 | 4.2 | 0 |
| 256 | Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. *Diagnostics*, **2021**, 11, | 3.8 | 3 |
| 255 | Imaging the "Hot Phase" of a Familiar Left-Dominant Arrhythmogenic Cardiomyopathy.. *Genes*, **2021**, 12, | 4.2 | 1 |
| 254 | MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. *Neurology International*, **2021**, 11, 230-254 | 0 | |
| 253 | Resilience and response of the congenital cardiac network in Italy during the COVID-19 pandemic. *Journal of Cardiovascular Medicine*, **2021**, 22, 9-13 | 1.9 | 4 |
| 252 | Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. *Journal of Cardiovascular Medicine*, **2021**, 22, 151-161 | 1.9 | 26 |
| 251 | The Role of Multimodality Imaging in Athlete's Heart Diagnosis: Current Status and Future Directions. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 5 |
| 250 | Left ventricular rotational mechanics in cardiac amyloidosis - reply. *International Journal of Cardiology*, **2021**, 345, 152 | 3.2 | 1 |
| 249 | A pilot clinical trial with losartan in Myhre syndrome. *American Journal of Medical Genetics, Part A*, **2021**, 185, 702-709 | 2.5 | 2 |
| 248 | Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. *Future Cardiology*, **2021**, 17, 647-654 | 1.3 | 5 |
| 247 | Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: the RIGHT heart international NETwork (RIGHT-NET). *International Journal of Cardiovascular Imaging*, **2021**, 37, 2151-2167 | 2.5 | 1 |

| | | | |
|---|---|---|---|
| 246 | Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2021**, 17, 303-313 | 3.3 | 4 |
| 245 | Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. *Pediatric Cardiology*, **2021**, 42, 1133-1140 | 2.1 | 2 |
| 244 | Drug-utilisation profiles and COVID-19. *Scientific Reports*, **2021**, 11, 8913 | 4.9 | 1 |
| 243 | Molecular Epidemiology of Mitochondrial Cardiomyopathy: A Search Among Mitochondrial and Nuclear Genes. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 5 |
| 242 | Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation. *Biomolecules*, **2021**, 11, | 5.9 | 1 |
| 241 | Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry. *Journal of Public Health*, **2021**, | 3.5 | 3 |
| 240 | Use of sacubitril/valsartan as 'bridge to transplant' in patients with end-stage hypertrophic cardiomyopathy. *Future Cardiology*, **2021**, 17, 89-94 | 1.3 | 1 |
| 239 | Feasibility and functional correlates of left atrial volume changes during stress echocardiography in chronic coronary syndromes. *International Journal of Cardiovascular Imaging*, **2021**, 37, 953-964 | 2.5 | 3 |
| 238 | Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. *International Journal of Environmental Research and Public Health*, **2021**, 18, | 4.6 | 17 |
| 237 | Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 781-789 | 4.1 | 2 |
| 236 | Novel autophagic vacuolar myopathies: Phenotype and genotype features. *Neuropathology and Applied Neurobiology*, **2021**, 47, 664-678 | 5.2 | 2 |
| 235 | Rare case of Kawasaki disease with cardiac tamponade and giant coronary artery aneurysms. *Cardiology in the Young*, **2021**, 31, 865-866 | 1 | 3 |
| 234 | Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1488-1490 | 4.5 | 1 |
| 233 | Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. *Frontiers in Pediatrics*, **2021**, 9, 632293 | 3.4 | 13 |
| 232 | Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. *European Journal of Preventive Cardiology*, **2021**, | 3.9 | 6 |
| 231 | Genetic evaluation in athletes and cascade family screening: reply. *European Journal of Preventive Cardiology*, **2021**, | 3.9 | 2 |
| 230 | A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. *European Journal of Preventive Cardiology*, **2021**, | 3.9 | 6 |
| 229 | External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. *International Journal of Cardiology*, **2021**, 339, 99-101 | 3.2 | 4 |

| | | | |
|---|---|---|---|
| 228 | Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. *ESC Heart Failure*, **2021**, | 3.7 | 4 |
| 227 | Advanced Heart Failure in Special Population-Pediatric Age. *Heart Failure Clinics*, **2021**, 17, 673-683 | 3.3 | 1 |
| 226 | Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy. *Current Cardiology Reports*, **2021**, 23, 165 | 4.2 | 0 |
| 225 | A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT Heart International NETwork (RIGHT-NET). *Cardiovascular Ultrasound*, **2021**, 19, 9 | 2.4 | 2 |
| 224 | Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003117 | 5.2 | 10 |
| 223 | Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database. *International Journal of Cardiology*, **2020**, 317, 103-110 | 3.2 | 5 |
| 222 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. *PLoS ONE*, **2020**, 15, e0233050 | 3.7 | 8 |
| 221 | Genetic analysis resolves differential diagnosis of a familial syndromic dilated cardiomyopathy: A new case of Alstrm syndrome. *Molecular Genetics & Genomic Medicine*, **2020**, 8, e1260 | 2.3 | 11 |
| 220 | Genotype-Phenotype Correlation: A Triple DNA Mutational Event in a Boy Entering Sport Conveys an Additional Pathogenicity Risk. *Genes*, **2020**, 11, | 4.2 | 10 |
| 219 | Atypical cardiac defects in patients with RASopathies: Updated data on CARNET study. *Birth Defects Research*, **2020**, 112, 725-731 | 2.9 | 6 |
| 218 | Cardiac imaging in congenital heart disease during the coronavirus disease-2019 pandemic: recommendations from the Working Group on Congenital Heart Disease of the Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2020**, 21, 467-471 | 1.9 | 7 |
| 217 | Methicillin-Resistant : Risk for General Infection and Endocarditis Among Athletes. *Antibiotics*, **2020**, 9, | 4.9 | 5 |
| 216 | An expert consensus document on the management of cardiovascular manifestations of Fabry disease. *European Journal of Heart Failure*, **2020**, 22, 1076-1096 | 12.3 | 33 |
| 215 | COVID-19 pandemia and inherited cardiomyopathies and channelopathies: a short term and long term perspective. *Orphanet Journal of Rare Diseases*, **2020**, 15, 157 | 4.2 | 6 |
| 214 | Yield and clinical significance of genetic screening in elite and amateur athletes. *European Journal of Preventive Cardiology*, **2020**, 2047487320934265 | 3.9 | 16 |
| 213 | Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. *BioFactors*, **2020**, 46, 367-380 | 6.1 | 28 |
| 212 | Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2020**, 21, 927-943 | 1.9 | 1 |
| 211 | Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. *Journal of Cardiac Failure*, **2020**, 26, 932-943 | 3.3 | 2 |

| | | | |
|---|---|---|---|
| 210 | Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. *European Journal of Internal Medicine*, **2020**, 71, 23-31 | 3.9 | 17 |
| 209 | Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. *ESC Heart Failure*, **2020**, 7, 371-380 | 3.7 | 11 |
| 208 | Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. *International Journal of Cardiology*, **2020**, 304, 86-92 | 3.2 | 9 |
| 207 | Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism. *European Journal of Preventive Cardiology*, **2020**, 27, 1906-1908 | 3.9 | 10 |
| 206 | Childhood obesity: an overview of laboratory medicine, exercise and microbiome. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1385-1406 | 5.9 | 4 |
| 205 | Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. *JAMA Cardiology*, **2020**, 5, 73-80 | 16.2 | 28 |
| 204 | Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. *European Journal of Internal Medicine*, **2020**, 72, 47-52 | 3.9 | 10 |
| 203 | Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers. *European Journal of Preventive Cardiology*, **2020**, 27, 65-71 | 3.9 | 0 |
| 202 | Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors. *European Journal of Preventive Cardiology*, **2020**, 2047487320940863 | 3.9 | 11 |
| 201 | Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 18 |
| 200 | Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. *Journal of Cardiovascular Pharmacology*, **2020**, 76, 173-180 | 3.1 | 21 |
| 199 | Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy. *Genes*, **2020**, 11, | 4.2 | 9 |
| 198 | Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. *International Journal of Environmental Research and Public Health*, **2020**, 17, | 4.6 | 8 |
| 197 | Surgical repair of bicuspid aortopathy at small diameters: Clinical and institutional factors. *Journal of Thoracic and Cardiovascular Surgery*, **2020**, 159, 2216-2226.e2 | 1.5 | 7 |
| 196 | Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 299, 186-191 | 3.2 | 32 |
| 195 | Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome. *Cardiology in the Young*, **2020**, 30, 663-667 | 1 | 5 |
| 194 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |
| 193 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |

| | | | |
|---|---|---|---|
| 192 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |
| 191 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |
| 190 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |
| 189 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050 | | |
| 188 | Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. *Genes*, **2019**, 10, | 4.2 | 8 |
| 187 | Berlin Heart EXCOR pediatric ventricular assist device in a patient with Sotos syndrome: a case report. *Journal of Medical Case Reports*, **2019**, 13, 286 | 1.2 | 1 |
| 186 | Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. *Expert Review of Cardiovascular Therapy*, **2019**, 17, 435-447 | 2.5 | 17 |
| 185 | Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2019**, 21, 553-576 | 12.3 | 118 |
| 184 | Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. *Internal and Emergency Medicine*, **2019**, 14, 621-625 | 3.7 | 26 |
| 183 | Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiology*, **2019**, 4, 918-927 | 16.2 | 67 |
| 182 | Clinical and Genetic Findings in Children with Neurofibromatosis Type 1, Legius Syndrome, and Other Related Neurocutaneous Disorders. *Genes*, **2019**, 10, | 4.2 | 16 |
| 181 | Left Atrial Volume during Stress Is Associated with Increased Risk of Arrhythmias in Patients with Hypertrophic Cardiomyopathy. *Journal of Cardiovascular Echography*, **2019**, 29, 1-6 | 0.6 | 6 |
| 180 | Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal. *EuroIntervention*, **2019**, 15, 411-417 | 3.1 | 9 |
| 179 | Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. *European Journal of Heart Failure*, **2019**, 21, 1586-1595 | 12.3 | 12 |
| 178 | Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. *European Journal of Heart Failure*, **2019**, 21, 208-217 | 12.3 | 33 |
| 177 | Sex-related differences in cardiomyopathies. *International Journal of Cardiology*, **2019**, 286, 239-243 | 3.2 | 16 |
| 176 | Treatments targeting inotropy. *European Heart Journal*, **2019**, 40, 3626-3644 | 9.5 | 51 |
| 175 | Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Heart*, **2019**, 105, 623-631 | 5.1 | 22 |

| | | | |
|---|---|---|---|
| 174 | Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. *ESC Heart Failure*, **2018**, 5, 267-274 | 3.7 | 4 |
| 173 | Common presentation of rare diseases: Aortic aneurysms & valves. *International Journal of Cardiology*, **2018**, 257, 358-365 | 3.2 | 2 |
| 172 | Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. *Journal of Cardiovascular Medicine*, **2018**, 19, 83-90 | 1.9 | 9 |
| 171 | A child with Myhre syndrome presenting with corectopia and tetralogy of Fallot. *American Journal of Medical Genetics, Part A*, **2018**, 176, 426-430 | 2.5 | 9 |
| 170 | Data on cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. *Data in Brief*, **2018**, 16, 649-654 | 1.2 | 5 |
| 169 | Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 601-610 | 4.1 | 23 |
| 168 | The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. *European Heart Journal*, **2018**, 39, 1784-1793 | 9.5 | 60 |
| 167 | Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. *Heart Failure Clinics*, **2018**, 14, 119-128 | 3.3 | 22 |
| 166 | Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. *Angiology*, **2018**, 69, 103-112 | 2.1 | 6 |
| 165 | Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. *European Journal of Heart Failure*, **2018**, 20, 700-710 | 12.3 | 51 |
| 164 | Dose-dependent efficacy of □blocker in patients with chronic heart failure and atrial fibrillation. *International Journal of Cardiology*, **2018**, 273, 141-146 | 3.2 | 10 |
| 163 | Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2018**, 271, 125-131 | 3.2 | 11 |
| 162 | Management of Bradyarrhythmias in Heart Failure: A Tailored Approach. *Advances in Experimental Medicine and Biology*, **2018**, 1067, 255-269 | 3.6 | 2 |
| 161 | Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease. *Journal of Cardiovascular Echography*, **2018**, 28, 120-123 | 0.6 | 6 |
| 160 | Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. *Journal of Cardiovascular Medicine*, **2018**, 19, 1-11 | 1.9 | 33 |
| 159 | Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 37 |
| 158 | Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists. *Italian Journal of Pediatrics*, **2018**, 44, 122 | 3.2 | 18 |
| 157 | Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update. *Journal of Clinical Medicine*, **2018**, 7, | 5.1 | 16 |

| | | | |
|---|---|---|---|
| 156 | A common polymorphism in the SCN5A gene is associated with dilated cardiomyopathy. *Journal of Cardiovascular Medicine*, **2018**, 19, 344-350 | 1.9 | 13 |
| 155 | The Right Heart International Network (RIGHT-NET): Rationale, Objectives, Methodology, and Clinical Implications. *Heart Failure Clinics*, **2018**, 14, 443-465 | 3.3 | 12 |
| 154 | Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. *Journal of Cardiovascular Medicine*, **2017**, 18, 249-254 | 1.9 | 7 |
| 153 | Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. *Cardiovascular Ultrasound*, **2017**, 15, 3 | 2.4 | 59 |
| 152 | Mitochondrial disease and the heart. *Heart*, **2017**, 103, 390-398 | 5.1 | 16 |
| 151 | Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. *Pediatrics and Neonatology* , **2017**, 58, 303-312 | 1.8 | 36 |
| 150 | Prognostic role of Eblocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. *European Journal of Heart Failure*, **2017**, 19, 904-914 | 12.3 | 19 |
| 149 | Predictors of atrial fibrillation in hypertrophic cardiomyopathy. *Heart*, **2017**, 103, 672-678 | 5.1 | 43 |
| 148 | Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. *European Journal of Preventive Cardiology*, **2017**, 24, 1220-1230 | 3.9 | 62 |
| 147 | Unexpected transesophageal echocardiography tee finding: mediastinal lipomatosis fakes an aortic intramural haematoma. *Quantitative Imaging in Medicine and Surgery*, **2017**, 7, 149-151 | 3.6 | 1 |
| 146 | B-lines with Lung Ultrasound: The Optimal Scan Technique at Rest and During Stress. *Ultrasound in Medicine and Biology*, **2017**, 43, 2558-2566 | 3.5 | 32 |
| 145 | Association between left ventricular perfusion defects and myocardial deformation indexes in heart transplantation recipients. *Echocardiography*, **2017**, 34, 1540-1543 | 1.5 | |
| 144 | Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. *International Journal of Cardiology*, **2017**, 243, 379-384 | 3.2 | 23 |
| 143 | Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. *International Journal of Cardiology*, **2017**, 245, 92-98 | 3.2 | 48 |
| 142 | Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. *Future Cardiology*, **2017**, 13, 521-527 | 1.3 | 2 |
| 141 | Exercise speckle-tracking strain imaging demonstrates impaired right ventricular contractile reserve in hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2017**, 227, 209-216 | 3.2 | 20 |
| 140 | Heart failure and anemia: Effects on prognostic variables. *European Journal of Internal Medicine*, **2017**, 37, 56-63 | 3.9 | 23 |
| 139 | Management of Arrhythmias in Heart Failure. *Journal of Cardiovascular Development and Disease*, **2017**, 4, | 4.2 | 32 |

| | | | |
|---|---|---|---|
| 138 | The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. *Mediators of Inflammation*, **2017**, 2017, 5620314 | 4.3 | 105 |
| 137 | MIB2 variants altering NOTCH signalling result in left ventricle hypertrabeculation/non-compaction and are associated with M□□rier-like gastropathy. *Human Molecular Genetics*, **2017**, 26, 33-43 | 5.6 | 7 |
| 136 | Heart Failure Progression in Hypertrophic Cardiomyopathy - Possible Insights From Cardiopulmonary Exercise Testing. *Circulation Journal*, **2016**, 80, 2204-11 | 2.9 | 25 |
| 135 | Genetics of Takotsubo Syndrome. *Heart Failure Clinics*, **2016**, 12, 499-506 | 3.3 | 8 |
| 134 | Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9, | 6.4 | 13 |
| 133 | Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *European Heart Journal*, **2016**, 37, 1850-8 | 9.5 | 473 |
| 132 | Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. *Heart*, **2016**, 102, 602-9 | 5.1 | 34 |
| 131 | Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. *Canadian Journal of Cardiology*, **2016**, 32, 754-9 | 3.8 | 14 |
| 130 | Aortitis. *Vascular Pharmacology*, **2016**, 80, 1-10 | 5.9 | 33 |
| 129 | The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. *International Journal of Cardiology*, **2016**, 203, 1067-72 | 3.2 | 25 |
| 128 | Anabolic-androgenic steroids and athlete's heart: When big is not beautiful....!. *International Journal of Cardiology*, **2016**, 203, 486-8 | 3.2 | 8 |
| 127 | Functional Studies and In Silico Analyses to Evaluate Non-Coding Variants in Inherited Cardiomyopathies. *International Journal of Molecular Sciences*, **2016**, 17, | 6.3 | 19 |
| 126 | Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group. *European Journal of Heart Failure*, **2016**, 18, 545-53 | 12.3 | 44 |
| 125 | Recurrent pericarditis in children and adolescents: a multicentre cohort study. *Journal of Cardiovascular Medicine*, **2016**, 17, 707-12 | 1.9 | 47 |
| 124 | Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases. *European Heart Journal: Acute Cardiovascular Care*, **2016**, 5, 416-33 | 4.3 | 26 |
| 123 | Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2016**, 118, 432-9 | 3 | 27 |
| 122 | Autosomal and X chromosome structural variants are associated with congenital heart defects in Turner syndrome: The NHLBI GenTAC registry. *American Journal of Medical Genetics, Part A*, **2016**, 170, 3157-3164 | 2.5 | 32 |
| 121 | Oesophagus perforation mimicking an acute chest pain syndrome. *Internal and Emergency Medicine*, **2015**, 10, 749-51 | 3.7 | 1 |

| | | | |
|---|---|---|---|
| 120 | Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. *European Journal of Preventive Cardiology*, **2015**, 22, 1046-55 | 3.9 | 24 |
| 119 | Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms?. *International Journal of Cardiology*, **2015**, 199, 189-92 | 3.2 | 7 |
| 118 | Right ventricular cardiomyopathies: a multidisciplinary approach to diagnosis. *Echocardiography*, **2015**, 32 Suppl 1, S75-94 | 1.5 | 11 |
| 117 | The pathology and pathobiology of bicuspid aortic valve: State of the art and novel research perspectives. *Journal of Pathology: Clinical Research*, **2015**, 1, 195-206 | 5.3 | 37 |
| 116 | Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). *European Journal of Heart Failure*, **2015**, 17, 837-45 | 12.3 | 77 |
| 115 | Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure--Application of Metabolic Exercise Cardiac Kidney Indexes Score. *Circulation Journal*, **2015**, 79, 2608-15 | 2.9 | 18 |
| 114 | Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction. *Circulation Journal*, **2015**, 79, 583-91 | 2.9 | 24 |
| 113 | Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. *European Journal of Internal Medicine*, **2015**, 26, 515-20 | 3.9 | 14 |
| 112 | Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica. *Revista Espanola De Cardiologia*, **2015**, 68, 63.e1-63.e52 | 1.5 | 4 |
| 111 | The Role of Multimodality Cardiac Imaging for the Assessment of Sports Eligibility in Patients with Bicuspid Aortic Valve. *Journal of Cardiovascular Echography*, **2015**, 25, 9-18 | 0.6 | |
| 110 | RAF1 mutations in childhood-onset dilated cardiomyopathy. *Nature Genetics*, **2014**, 46, 635-639 | 36.3 | 54 |
| 109 | Takotsubo cardiomyopathy: an integrated multi-imaging approach. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 366-77 | 4.1 | 51 |
| 108 | DNA sequence capture and next-generation sequencing for the molecular diagnosis of genetic cardiomyopathies. *Journal of Molecular Diagnostics*, **2014**, 16, 32-44 | 5.1 | 36 |
| 107 | Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. *Current Atherosclerosis Reports*, **2014**, 16, 435 | 6 | 270 |
| 106 | Normal values of aortic root dimensions in healthy adults. *American Journal of Cardiology*, **2014**, 114, 921-7 | 3 | 59 |
| 105 | 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *European Heart Journal*, **2014**, 35, 2733-79 | 9.5 | 2361 |
| 104 | A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *European Heart Journal*, **2014**, 35, 2010-20 | 9.5 | 570 |
| 103 | A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium). *Journal of the American College of Cardiology*, **2014**, 64, 832-9 | 15.1 | 119 |

| | | | |
|---|---|---|---|
| 102 | Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2014**, 114, 769-76 | 3 | 56 |
| 101 | LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies. *BMC Medical Genetics*, **2014**, 15, 44 | 2.1 | 25 |
| 100 | Genetic analysis in a family affected by sick sinus syndrome may reduce the sudden death risk in a young aspiring competitive athlete. *International Journal of Cardiology*, **2014**, 170, e63-5 | 3.2 | 19 |
| 99 | Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon). *Circulation*, **2014**, 129, 2691-704 | 16.7 | 227 |
| 98 | Overall and allele-specific expression of the SMC1A gene in female Cornelia de Lange syndrome patients and healthy controls. *Epigenetics*, **2014**, 9, 973-9 | 5.7 | 9 |
| 97 | Cardiac resynchronization therapy in cardiomyopathies. *Journal of Cardiovascular Medicine*, **2014**, 15, 92-9 | 1.9 | 2 |
| 96 | Surgical treatment of bicuspid aortic valve disease: knowledge gaps and research perspectives. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 147, 1749-57, 1757.e1 | 1.5 | 65 |
| 95 | Cardiomyopathy in children: importance of aetiology in prognosis. *Lancet, The*, **2014**, 383, 781-2 | 40 | 1 |
| 94 | Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. *Internal and Emergency Medicine*, **2014**, 9, 43-50 | 3.7 | 7 |
| 93 | Adipose tissue and vascular inflammation in coronary artery disease. *World Journal of Cardiology*, **2014**, 6, 539-54 | 2.1 | 32 |
| 92 | Digenic mutational inheritance of the integrin alpha 7 and the myosin heavy chain 7B genes causes congenital myopathy with left ventricular non-compact cardiomyopathy. *Orphanet Journal of Rare Diseases*, **2013**, 8, 91 | 4.2 | 32 |
| 91 | Prognostic value of indeterminable anaerobic threshold in heart failure. *Circulation: Heart Failure*, **2013**, 6, 977-87 | 7.6 | 39 |
| 90 | Takotsubo cardiomyopathy: overview. *Heart Failure Clinics*, **2013**, 9, 249-66, x | 3.3 | 47 |
| 89 | Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. *International Journal of Cardiology*, **2013**, 167, 2710-8 | 3.2 | 131 |
| 88 | Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: role of peak oxygen consumption. *International Journal of Cardiology*, **2013**, 168, 5078-81 | 3.2 | 21 |
| 87 | Low output syndrome masking aortic regurgitation in a Marfan patient. Usefulness of 3D transthoracic echocardiography and heart team. *International Journal of Cardiology*, **2013**, 165, e55-6 | 3.2 | 1 |
| 86 | Takotsubo cardiomyopathy: do the genetics matter?. *Heart Failure Clinics*, **2013**, 9, 207-16, ix | 3.3 | 20 |
| 85 | Skeletal muscle involvement in cardiomyopathies. *Journal of Cardiovascular Medicine*, **2013**, 14, 837-61 | 1.9 | 12 |

| | | | |
|---|---|---|---|
| 84 | Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. *Future Cardiology*, **2013**, 9, 519-34 | 1.3 | 9 |
| 83 | Obesity, Inflammation, and Vascular Disease: Novel Insight in the Role of Adipose Tissue **2013**, 311-326 | | |
| 82 | Right heart morphology and function in heart transplantation recipients. *Journal of Cardiovascular Medicine*, **2013**, 14, 648-58 | 1.9 | 22 |
| 81 | Assessment of left-ventricular mass and remodeling in obese adolescents: M-mode, 2D or 3D echocardiography?. *Journal of Cardiovascular Medicine*, **2013**, 14, 144-9 | 1.9 | 14 |
| 80 | La risonanza magnetica cardiovascolare nella valutazione dello scompenso cardiaco: dalla morfologia alla caratterizzazione tissutale. *Journal of Cardiovascular Echography*, **2012**, 22, 60-73 | 0.6 | |
| 79 | Early left ventricular abnormalities in children with heterozygous familial hypercholesterolemia. *Journal of the American Society of Echocardiography*, **2012**, 25, 1075-82 | 5.8 | 22 |
| 78 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. *Future Cardiology*, **2012**, 8, 71-88 | 1.3 | 38 |
| 77 | Usefulness of bidimensional strain imaging for predicting outcome in asymptomatic patients aged ≥16 years with isolated moderate to severe aortic regurgitation. *American Journal of Cardiology*, **2012**, 110, 1051-5 | 3 | 25 |
| 76 | Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. *Internal and Emergency Medicine*, **2012**, 7, 425-30 | 3.7 | 22 |
| 75 | Aortic stiffness and distensibility in top-level athletes. *Journal of the American Society of Echocardiography*, **2012**, 25, 561-7 | 5.8 | 26 |
| 74 | Right ventricular morphology and function in top-level athletes: a three-dimensional echocardiographic study. *Journal of the American Society of Echocardiography*, **2012**, 25, 1268-76 | 5.8 | 58 |
| 73 | La stretta correlazione tra la funzione ventricolare destra valutata all'ecografia tridimensionale e la capacità funzionale nei pazienti con cardiomiopatia dilatativa. *Journal of Cardiovascular Echography*, **2011**, 21, 126-134 | 0.6 | |
| 72 | Right ventricular ejection fraction and left ventricular dyssynchrony by 3D echo correlate with functional impairment in patients with dilated cardiomyopathy. *Journal of Cardiac Failure*, **2011**, 17, 309-17 | 3.3 | 12 |
| 71 | Search of somatic GATA4 and NKX2.5 gene mutations in sporadic septal heart defects. *European Journal of Medical Genetics*, **2011**, 54, 306-9 | 2.6 | 31 |
| 70 | A new era in cardiogenetics. *Neurology International*, **2011**, 1, 1 | 0 | 0 |
| 69 | Association between right ventricular two-dimensional strain and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy. *Journal of Cardiovascular Medicine*, **2011**, 12, 625-34 | 1.9 | 11 |
| 68 | Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy. *Acta Cardiologica*, **2011**, 66, 787-90 | 0.9 | 40 |
| 67 | Contemporary evidence of coronary atherosclerotic disease and myocardial bridge on left anterior descending artery in a patient with a nonobstructive hypertrophic cardiomyopathy. *Journal of Cardiovascular Medicine*, **2011**, 12, 510-2 | 1.9 | 1 |

| | | | |
|---|---|---|---|
| 66 | Range in pulmonary artery systolic pressure among highly trained athletes. *Chest*, **2011**, 139, 788-794 | 5.3 | 53 |
| 65 | Impact of obesity on left ventricular geometry and function in pediatric patients after successful aortic coarctation repair. *Echocardiography*, **2011**, 28, 907-12 | 1.5 | 4 |
| 64 | Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. *Internal and Emergency Medicine*, **2011**, 6, 503-7 | 3.7 | 11 |
| 63 | Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. *American Journal of Medical Genetics, Part A*, **2011**, 155A, 486-507 | 2.5 | 84 |
| 62 | Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-B-dependent pathway. *Journal of Vascular Research*, **2011**, 48, 59-66 | 1.9 | 49 |
| 61 | Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. *European Journal of Echocardiography*, **2011**, 12, 841-9 | | 49 |
| 60 | Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. *Journal of Human Hypertension*, **2011**, 25, 739-45 | 2.6 | 39 |
| 59 | Right ventricular myocardial involvement in either physiological or pathological left ventricular hypertrophy: an ultrasound speckle-tracking two-dimensional strain analysis. *European Journal of Echocardiography*, **2010**, 11, 492-500 | | 60 |
| 58 | Cardiac manifestations of mitochondrial disorders: reply. *European Journal of Heart Failure*, **2010**, 12, 637-638 | 12.3 | |
| 57 | Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. *European Journal of Heart Failure*, **2010**, 12, 114-21 | 12.3 | 89 |
| 56 | Familial transposition of the great arteries caused by multiple mutations in laterality genes. *Heart*, **2010**, 96, 673-7 | 5.1 | 100 |
| 55 | Left ventricular myocardial velocities and deformation indexes in top-level athletes. *Journal of the American Society of Echocardiography*, **2010**, 23, 1281-8 | 5.8 | 62 |
| 54 | Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. *Journal of the American Society of Echocardiography*, **2010**, 23, 581-90 | 5.8 | 39 |
| 53 | Transverse strain predicts exercise capacity in systemic right ventricle patients. *International Journal of Cardiology*, **2010**, 145, 193-196 | 3.2 | 28 |
| 52 | Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. *Cytokine*, **2010**, 50, 245-7 | 4 | 12 |
| 51 | Left atrial volume index in highly trained athletes. *American Heart Journal*, **2010**, 159, 1155-61 | 4.9 | 124 |
| 50 | Right ventricular hypertrabeculation associated with double-outlet left ventricle: exaggeration of a normal pattern or right ventricular cardiomyopathy?. *Journal of Cardiovascular Medicine*, **2010**, 11, 193-5 | 1.9 | 4 |
| 49 | Inflammation: The Link Between Obesity and Cardiovascular Risk. *Current Cardiovascular Risk Reports*, **2010**, 4, 101-111 | 0.9 | 1 |

| | | | |
|---|---|---|---|
| 48 | Clinical course and risk profile in adolescents with idiopathic dilated cardiomyopathy. *American Journal of Cardiology*, **2010**, 105, 716-20 | 3 | 3 |
| 47 | Aortic root dimensions in elite athletes. *American Journal of Cardiology*, **2010**, 105, 1629-34 | 3 | 72 |
| 46 | Left ventricular non compaction in children. *Congenital Heart Disease*, **2010**, 5, 384-97 | 3.1 | 16 |
| 45 | Hypertrophic cardiomyopathy in a girl with Cornelia de Lange syndrome due to mutation in SMC1A. *American Journal of Medical Genetics, Part A*, **2010**, 152A, 2127-9 | 2.5 | 21 |
| 44 | Effects of global longitudinal strain and total scar burden on response to cardiac resynchronization therapy in patients with ischaemic dilated cardiomyopathy. *European Journal of Heart Failure*, **2009**, 11, 58-67 | 12.3 | 52 |
| 43 | Right atrial size and deformation in patients with dilated cardiomyopathy undergoing cardiac resynchronization therapy. *European Journal of Heart Failure*, **2009**, 11, 1169-77 | 12.3 | 34 |
| 42 | Right ventricular myocardial function in patients with either idiopathic or ischemic dilated cardiomyopathy without clinical sign of right heart failure: effects of cardiac resynchronization therapy. *PACE - Pacing and Clinical Electrophysiology*, **2009**, 32, 1017-29 | 1.6 | 35 |
| 41 | A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy. *Clinical Genetics*, **2009**, 76, 91-101 | 4 | 30 |
| 40 | Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 142-8 | 5.8 | 46 |
| 39 | Association between left atrial myocardial function and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy: a two-dimensional speckle strain study. *International Journal of Cardiology*, **2009**, 132, 354-63 | 3.2 | 70 |
| 38 | Two-dimensional strain and atrial function: a study on patients after percutaneous closure of atrial septal defect. *European Journal of Echocardiography*, **2009**, 10, 256-9 | | 27 |
| 37 | Severe, obstructive biventricular hypertrophy in a patient with Costello syndrome: Clinical impact and management. *International Journal of Cardiology*, **2008**, 130, e108-10 | 3.2 | 7 |
| 36 | Atrial myocardial deformation properties in obese nonhypertensive children. *Journal of the American Society of Echocardiography*, **2008**, 21, 151-6 | 5.8 | 40 |
| 35 | Left atrial myocardial function in either physiological or pathological left ventricular hypertrophy: a two-dimensional speckle strain study. *British Journal of Sports Medicine*, **2008**, 42, 696-702 | 10.3 | 56 |
| 34 | A standard echocardiographic and tissue Doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. *Cardiology in the Young*, **2008**, 18, 575-80 | 1 | 14 |
| 33 | The role of adiposity as a determinant of an inflammatory milieu. *Journal of Cardiovascular Medicine* , **2008**, 9, 450-60 | 1.9 | 28 |
| 32 | Trisomy 18 and hypertrophy cardiomyopathy in an 18-year-old woman. *American Journal of Medical Genetics, Part A*, **2008**, 146A, 327-9 | 2.5 | 5 |
| 31 | Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. *American Journal of Medical Genetics, Part A*, **2008**, 146A, 620-8 | 2.5 | 40 |

| | | | |
|---|---|---|---|
| 30 | Severe, early onset hypertrophic cardiomyopathy in a family with LEOPARD syndrome. *Journal of Prenatal Medicine*, **2008**, 2, 24-6 | | 4 |
| 29 | Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. *American Journal of Cardiology*, **2007**, 100, 736-41 | 3 | 121 |
| 28 | Effect of dynamic myocardial dyssynchrony on mitral regurgitation during supine bicycle exercise stress echocardiography in patients with idiopathic dilated cardiomyopathy and 'narrow' QRS. *European Heart Journal*, **2007**, 28, 1004-11 | 9.5 | 50 |
| 27 | Abnormal regional myocardial deformation properties and increased aortic stiffness in normotensive patients with aortic coarctation despite successful correction: an ABPM, standard echocardiography and strain rate imaging study. *Clinical Science*, **2007**, 113, 259-66 | 6.5 | 31 |
| 26 | Echocardiography in congenital heart disease: usefulness, limits and new techniques. *Journal of Cardiovascular Medicine*, **2007**, 8, 17-22 | 1.9 | 15 |
| 25 | Left ventricle myocardial mechanics and textural properties in patients with Williams syndrome. *Journal of Cardiovascular Medicine*, **2007**, 8, 330-6 | 1.9 | 3 |
| 24 | Myocardial infarction in a young athlete with non-obstructive hypertrophic cardiomyopathy and normal coronary arteries. *International Journal of Cardiology*, **2007**, 115, e71-3 | 3.2 | 6 |
| 23 | Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischaemic dilated cardiomyopathy: a two-dimensional speckle strain study. *European Heart Journal*, **2007**, 28, 2738-48 | 9.5 | 92 |
| 22 | LEOPARD syndrome: clinical diagnosis in the first year of life. *American Journal of Medical Genetics, Part A*, **2006**, 140, 740-6 | 2.5 | 102 |
| 21 | Familial recurrence of anomalous origin of right pulmonary artery from the aorta. *American Journal of Medical Genetics, Part A*, **2006**, 140, 794-6 | 2.5 | |
| 20 | Abnormal myocardial deformation properties in obese, non-hypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. *European Heart Journal*, **2006**, 27, 2689-95 | 9.5 | 131 |
| 19 | Is sudden cardiac death predictable in LEOPARD syndrome?. *Cardiology in the Young*, **2006**, 16, 599-601 | 1 | 10 |
| 18 | Complete atrioventricular canal. *Orphanet Journal of Rare Diseases*, **2006**, 1, 8 | 4.2 | 31 |
| 17 | Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy. *European Journal of Medical Genetics*, **2006**, 49, 426-30 | 2.6 | 11 |
| 16 | Left ventricular hypertrophy in Caucasian master athletes: Differences with hypertension and hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2006**, 111, 113-9 | 3.2 | 21 |
| 15 | Diffuse coronary dilation in a young patient with LEOPARD syndrome. *International Journal of Cardiology*, **2006**, 112, e35-7 | 3.2 | 7 |
| 14 | Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation. *Neuromuscular Disorders*, **2006**, 16, 548-52 | 2.9 | 68 |
| 13 | Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. *Journal of Cardiovascular Medicine*, **2006**, 7, 711-3 | 1.9 | 8 |

| | | | |
|---|---|---|---|
| 12 | PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". *European Journal of Pediatrics*, **2006**, 165, 803-5 | 4.1 | 26 |
| 11 | Early myocardial abnormalities in asymptomatic patients with severe isolated congenital aortic regurgitation: an ultrasound tissue characterization and strain rate study. *Journal of the American Society of Echocardiography*, **2005**, 18, 122-7 | 5.8 | 13 |
| 10 | Backscatter evaluation of myocardial functional and textural findings in children with right ventricular pressure and/or volume overload. *American Journal of Cardiology*, **2004**, 93, 594-7 | 3 | 11 |
| 9 | Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2004**, 70, 95-8 | | 11 |
| 8 | Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. *Journal of the American College of Cardiology*, **2004**, 44, 398-405 | 15.1 | 56 |
| 7 | Subclinical hypothyroidism and Down's syndrome; studies on myocardial structure and function. *Archives of Disease in Childhood*, **2003**, 88, 1005-8 | 2.2 | 19 |
| 6 | Right ventricular myocardial adaptation to different training protocols in top-level athletes. *Echocardiography*, **2003**, 20, 329-36 | 1.5 | 49 |
| 5 | Myocardial ultrasound tissue characterization in patients with hypertrophic cardiomyopathy: noninvasive evidence of electrical and textural substrate for ventricular arrhythmias. *Journal of the American Society of Echocardiography*, **2003**, 16, 803-7 | 5.8 | 12 |
| 4 | Left ventricular remodeling, mechanics, and tissue characterization in congenital aortic stenosis. *Journal of the American Society of Echocardiography*, **2003**, 16, 214-20 | 5.8 | 25 |
| 3 | Feasibility and usefulness of right ventricular ultrasonic tissue characterization with integrated backscatter in patients with unsuccessfully operatively "repaired" tetralogy of Fallot. *American Journal of Cardiology*, **2002**, 90, 669-71 | 3 | 8 |
| 2 | Association between left ventricular structure and cardiac performance during effort in two morphological forms of athlete's heart. *International Journal of Cardiology*, **2002**, 86, 177-84 | 3.2 | 92 |
| 1 | Effects of different training protocols on left ventricular myocardial function in competitive athletes: a Doppler tissue imaging study. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2002**, 3, 34-40 | | 11 |